![Vincent Brichard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vincent Brichard
Directeur/Membre du Conseil chez
eTheRNA immunotherapies NV
Profil
Vincent Brichard currently works at ImCyse SA, as Director, eTheRNA immunotherapies NV, as Director, Imcheck Therapeutics SAS, as Director from 2019, FoRx Therapeutics AG, as Director, Nouscom Srl, as Director, Egle Therapeutics SAS, as Director from 2025, and EQT Life Sciences Group BV, as Venture Partner from 2015.
Dr. Brichard also formerly worked at Kiadis Pharma BV, as Member-Supervisory Board, Celyad Oncology SA, as Vice President, and Kiadis Pharma NV, as Independent Member-Supervisory Board.
Dr. Brichard received his doctorate degree from Katholieke Universiteit Leuven, graduate degree from Université Catholique de Louvain, Masters Business Admin degree from Harvard Business School, and doctorate degree from Ludwig Institute For Cancer Research (Belgium).
Postes actifs de Vincent Brichard
| Sociétés | Poste | Début |
|---|---|---|
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology Operates as a technology platform that develops mRNA and lipid nanoparticle therapeutics | Directeur/Membre du Conseil | - |
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance EQT Life Sciences invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, medical devices, diagnostics and healthtech sectors. It provides financing for early and later stage capital requirements with an investment size of EUR 10 – 60 million. | Private Equity Investor | 01/01/2015 |
Imcheck Therapeutics SAS
 Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research | Directeur/Membre du Conseil | 04/12/2019 |
FoRx Therapeutics AG
 FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops cancer treatment compounds | Directeur/Membre du Conseil | - |
Egle Therapeutics SAS
 Egle Therapeutics SAS BiotechnologyHealth Technology Operates as a biotechnology company that designs modulate regulatory T cells to balance immunity for the treatment of cancer and autoimmune diseases | Directeur/Membre du Conseil | - |
ImCyse SA
 ImCyse SA BiotechnologyHealth Technology Engages in the development of curative therapies in the field of immune and allergic pathologies | Directeur/Membre du Conseil | - |
Nouscom Srl
 Nouscom Srl Miscellaneous Commercial ServicesCommercial Services Operates as a next-generation immunotherapy company that develops engineered viral vectored vaccines for treatment of cancer | Directeur/Membre du Conseil | - |
Anciens postes connus de Vincent Brichard
| Sociétés | Poste | Fin |
|---|---|---|
| KIADIS PHARMA N.V. | Directeur/Membre du Conseil | - |
| CELYAD ONCOLOGY SA | Corporate Officer/Principal | - |
| ░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Vincent Brichard
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
17
Relations au 1er degré
14
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
LSP Management Group BV
LSP Management Group BV Investment ManagersFinance EQT Life Sciences invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, medical devices, diagnostics and healthtech sectors. It provides financing for early and later stage capital requirements with an investment size of EUR 10 – 60 million. | Finance |
Katholieke Universiteit Leuven
 Katholieke Universiteit Leuven Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kiadis Pharma BV
 Kiadis Pharma BV Pharmaceuticals: MajorHealth Technology Operates as a is a clinical stage biopharmaceutical company focused on research, development and future commercialization of cell based immunotherapy products | Health Technology |
Université Catholique de Louvain
 Université Catholique de Louvain Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Celyad Oncology SA
 Celyad Oncology SA BiotechnologyHealth Technology Develops immuno-oncology and cardiology products | Health Technology |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology Engages in the development of curative therapies in the field of immune and allergic pathologies | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kiadis Pharma NV
 Kiadis Pharma NV Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company focused on research, development and commercialization of cell based immunotherapy products | Health Technology |
Ludwig Institute For Cancer Research (Belgium)
 Ludwig Institute For Cancer Research (Belgium) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology Operates as a technology platform that develops mRNA and lipid nanoparticle therapeutics | Health Technology |
Imcheck Therapeutics SAS
Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research | Health Technology |
FoRx Therapeutics AG
FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops cancer treatment compounds | Health Technology |
Nouscom Srl
Nouscom Srl Miscellaneous Commercial ServicesCommercial Services Operates as a next-generation immunotherapy company that develops engineered viral vectored vaccines for treatment of cancer | Commercial Services |
Egle Therapeutics SAS
Egle Therapeutics SAS BiotechnologyHealth Technology Operates as a biotechnology company that designs modulate regulatory T cells to balance immunity for the treatment of cancer and autoimmune diseases | Health Technology |
Choisissez Zonebourse 
